FDA Advises Sarepta to Lift Pause and Resume ELEVIDYS Shipments for Ambulatory Duchenne Patients
Sarepta Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has informed the company it may lift its voluntary pause on shipments of ELEVIDYS (delandistrogene…
Read More...
Read More...
